Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis

NCT01885078 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01885078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01885078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
June 27, 2013
Completion date
November 12, 2020
Enrollment
2,877 (actual)
Sites
408

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis